CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 498 enrolled
Drug / intervention
MC2-01 cream +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03802344
NCT03802344Phase 3Completed
CompareCT.gov

A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris

MC2 Therapeutics·interventional·Posted Jan 14, 2019·Updated Dec 16, 2020

In Brief

A Phase 3 clinical trial evaluating MC2-01 cream, Cal/BDP combination, and 1 other intervention for Psoriasis Vulgaris. Completed, enrolled 498 participants across 2 sites in 2 countries.

Detailed Summary

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCzechia, Germany
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 14, 2019
Enrollment StartDec 12, 2018
Primary CompletionOct 2, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.5 years ago

Interventions

MC2-01 creamdrug

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream

Cal/BDP combinationdrug

Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%

Vehicledrug

Vehicle cream